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Parkinson’s disease dementia: a neural
networks perspective
James Gratwicke, Marjan Jahanshahi and Thomas Foltynie
In the long-term, with progression of the illness, Parkinson’s disease dementia affects up to 90% of patients with Parkinson’s
disease. With increasing life expectancy in western countries, Parkinson’s disease dementia is set to become even more prevalent in
the future. However, current treatments only give modest symptomatic beneﬁt at best. New treatments are slow in development
because unlike the pathological processes underlying the motor deﬁcits of Parkinson’s disease, the neural mechanisms underlying
the dementing process and its associated cognitive deﬁcits are still poorly understood. Recent insights from neuroscience research
have begun to unravel the heterogeneous involvement of several distinct neural networks underlying the cognitive deﬁcits in
Parkinson’s disease dementia, and their modulation by both dopaminergic and non-dopaminergic transmitter systems in the
brain. In this review we collate emerging evidence regarding these distinct brain networks to give a novel perspective on the
pathological mechanisms underlying Parkinson’s disease dementia, and discuss how this may offer new therapeutic opportunities.
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Introduction
Parkinson’s disease dementia (PDD) is a late complication
of Parkinson’s disease, with a cumulative prevalence of
75–90% of those with a disease duration of 10 years or
more (Buter et al., 2008; Hely et al., 2008; Aarsland and
Kurz, 2010). It’s development negatively impacts activities
of daily living (Rosenthal et al., 2010), and confers signiﬁ-
cantly increased morbidity and mortality (Reid et al., 1996;
Levy et al., 2002b). It is now widely recognized that the
clinical phenotype of PDD extends beyond the classical
dysexecutive syndrome seen in early Parkinson’s disease
to include additional deﬁcits in recognition memory, atten-
tion processes and visual perception (Pagonabarraga and
Kulisevsky, 2012; Kehagia et al., 2013), as well as visual
hallucinations and cognitive ﬂuctuations (Emre, 2003). This
constellation of features was recently made explicit in the
diagnostic criteria for PDD (Emre et al., 2007). However,
in stark contrast to the nigrostriatal pathology underlying
the motor aspects of the disorder (Fahn et al., 1971; Hirsch
et al., 1988), the pathophysiological mechanisms underly-
ing PDD remain obscure, which hinders the development of
new therapies.
One major difﬁculty in determining the pathological
mechanisms contributing to PDD is that the underlying cel-
lular-level pathology is heterogeneous, with Lewy bodies,
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 neuroﬁbrillary tangles, senile plaques, microvascular disease
and argyrophilic inclusions all contributing (Irwin et al.,
2012; Del Tredici and Braak, 2013; Horvath et al., 2013;
Halliday et al., 2014). The anatomical distribution of such
pathology varies between different cases (Colosimo et al.,
2003; Galvin et al., 2006) and does not always correspond
with clinical symptoms. For example, in one large neuro-
pathological series, 55% of Parkinson’s disease cases with
Braak stage 5-6 pathology (i.e. limbic and neocortical Lewy
bodies) lacked clinical evidence of dementia (Parkkinen
et al., 2008). Complicating the picture further, several
genes are known to confer an increased risk for develop-
ment of PDD, including alpha-synuclein (SNCA) and glu-
cocerebrosidase (GBA) mutations, the apolipoprotein "4
(APOE4) allele and the microtubule-associated protein
tau (MAPT) H1 haplotype (reviewed in Halliday et al.,
2014), all of which are likely to contribute to cognitive
decline via different mechanisms. In illustration of this, a
recent study showed that newly diagnosed patients with
Parkinson’s disease carrying the APOE4 allele show
reduced activity in the medial temporal lobe (MTL) net-
work during memory tasks, whereas MAPT H1 homozy-
gotes instead show reduced activity in the posterior visual
network during visuospatial tasks (Nombela et al., 2014).
The complex and varying milieu of neuropathological and
genetic factors underlying the development of PDD renders it
difﬁcult to provide a generalized pathophysiological mechan-
ism across patients from this perspective to account for the
common clinical picture seen. However, diverse molecular
and cellular pathologies can give rise to common patterns
of dysfunction at the neural systems level, and therefore
recent studies have begun to characterize the mechanisms
underlying Parkinsonian dementia from this perspective,
which provides a more generalizable model. In this review
we collate recent evidence from neuropsychological, pharma-
cological, imaging and electrophysiological approaches to
present a novel systems-level perspective on the pathophysio-
logical mechanisms underlying PDD: the syndrome repre-
sents variable and interacting dysfunction in a number of
diffusely distributed, yet interrelated, neural networks that
contribute to distinct cognitive processes, including fronto-
striatal, mesocortical, corticopetal cholinergic, fronto-par-
ietal, medial temporal and noradrenergic networks. These
are in turn differentially inﬂuenced by dopaminergic, cholin-
ergic, and noradrenergic deﬁcits. We propose that viewing
the development of PDD from this dysfunctional networks
perspective can provide novel insights and opportunities for
development of new therapies.
To provide conceptual order to an otherwise anarchic
data set we will approach discussion of these networks
by addressing in turn each of the major cognitive domains
affected by PDD (executive function, attention, memory
and visual perceptual ability) and describing the major net-
work dysfunctions underlying deﬁcits in those areas.
However, the reader must bear in mind that the division
of cognitive ability into these compartmentalized domains
is inherently artiﬁcial, which in turn renders the assignment
of neural networks to the subservience of a constrained
domain equally so. The reality is that all these cognitive
networks interact and overlap in a complex manner, and
the generation of any conceptualized cognitive function
such as ‘memory’ is ultimately inﬂuenced by many of
their individual distributed actions. Nevertheless, evidence
suggests that particular neural networks are more strongly
implicated in mediating certain cognitive functions than
others, which gives validity to approaching the discussion
in this manner. Of note the ﬁfth domain, language, is rela-
tively preserved in PDD [the main deﬁcit in this area,
impaired verbal ﬂuency, is actually part of the dysexecutive
syndrome (impaired self-generated search, Emre, 2003) and
consequently is not discussed].
Following discussion of the dysfunctional cognitive
networks underlying PDD we go on to address three
important issues that arise from taking this perspective.
First we consider how this network perspective relates
back to the cellular neuropathology of PDD. Second we
discuss the relevance of this network viewpoint to current
clinical practice, including factors predicting the develop-
ment of PDD, and the relation to current available thera-
pies. Finally, we discuss how this neural network
perspective on PDD may offer new therapeutic opportu-
nities to directly modulate network function, and experi-
mental treatments in this area.
Executive dysfunction:
fronto-striatal, mesocortical
and noradrenergic networks
‘Executive function’ is an umbrella term encompassing
several cognitive abilities, including problem-solving, plan-
ning/sequencing, rule-shifting/maintenance, task-switching,
manipulation in working memory and response inhibition
(Dubois and Pillon, 1997; Kehagia et al., 2010; Parker
et al., 2013; see Dirnberger and Jahanshahi, 2013 for
review). Some also regard allocation of attention as an ex-
ecutive function (Kehagia et al., 2010), though here we will
consider it a separate cognitive domain. Executive dysfunc-
tion is often present in Parkinson’s disease from the point
of diagnosis (Lees and Smith, 1983; Foltynie et al., 2004a;
Muslimovic et al., 2005), and may even be part of a pre-
motor prodromal syndrome (Goldman et al., 2014b).
Executive impairment worsens with disease progression
(Pagonabarraga and Kulisevsky, 2012; Christopher et al.,
2014), and in some series has been found to be predictive
of conversion to PDD, though this remains controversial
(Levy et al., 2002a; Woods and Tro ¨ster, 2003; Janvin
et al., 2005; Lee et al., 2013; Biundo et al., 2014). From
the patient perspective, progressive difﬁculties with concen-
tration, retaining information, planning and organizational
skills start interfering with social and occupational function
(Bronnick et al., 2006). The Montreal Cognitive
Assessment is sensitive to the detection of executive deﬁcits
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 in Parkinson’s disease (Zadikoff et al., 2008; Nazem et al.,
2009), and consequently is a more sensitive tool for detec-
tion of PDD in the clinic than the traditional Mini-Mental
State Examination (MMSE) (Hoops et al., 2009; Burdick
et al., 2014).
Executive dysfunction is due to
disruption of the fronto-striatal
dopamine network
The prefrontal cortices are implicated in executive function
(Milner, 1982, 1995; Norman and Shallice, 1986; Fuster,
2008), and distinct areas of prefrontal cortex have strong
functional connections with the striatum via parallel dopa-
mine-dependent cortico-striatal loops (Alexander et al.,
1986; Middleton and Strick, 2000) (Figs 1 and 3).
Functional MRI imaging in patients with Parkinson’s dis-
ease relates executive impairments on set shifting and
working memory tasks to hypo-activation within the
fronto-striatal loops connecting dorsolateral and
ventrolateral prefrontal cortices, striatum and thalamus
(Lewis et al., 2003; Monchi et al., 2004, 2007; Au et al.,
2012). However, such hypo-activation was only present
during task phases that speciﬁcally required co-activation
with the striatum in controls, indicating that striatal dys-
function was the determining factor in executive impair-
ment in Parkinson’s disease rather than frontal
dysfunction. Both the globus pallidus internus and caudate
are heavily affected by dopaminergic degeneration (Taylor
et al., 1986), and PET studies have speciﬁcally implicated
dysfunction of these two structures in interruption of
normal processing in the fronto-striatal network; for ex-
ample, patients with Parkinson’s disease demonstrating ex-
ecutive impairments on tasks involving planning (Owen
et al., 1998) or random number generation (Dirnberger
et al., 2005) show signiﬁcantly altered outﬂow activity
from the pallidum to the frontal cortices. In addition,
other studies have shown strong correlations between
dopamine depletion in the head of the caudate and deﬁcits
on executive tasks such as object alternation (Marie ´ et al.,
1999) and the Stroop Test (Bru ¨ck et al., 2001).
Figure 1 The major subcortical neural networks affected in PDD (according to their dominant neurotransmitters). In this
3D representation the medial surface of the right hemisphere of the human brain is closest to the viewer in both images. A = amygdala;
AC = anterior commissure (lateral aspect); C = caudate; Cg = cingulate gyrus; DLPFC = dorsolateral prefrontal cortex; GPi = globus pallidus
(internus); IN = insular cortex; LC = locus ceruleus; P = putamen; SN = substantia nigra; T = thalamus; VLPFC = ventrolateral prefrontal cortex;
VTA = ventral tegmental area.
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 Therefore, the prevailing view is that executive dysfunc-
tion in PDD is due to dopaminergic depletion in the stri-
atum disrupting transmission in the fronto-striatal network
(Mortimer et al., 1982; Dubois et al., 1994; Owen et al.,
1995; Zgaljardic et al., 2003; Owen, 2004; Pagonabarraga
and Kulisevsky, 2012; Kehagia et al., 2013).
Degeneration in the mesocortical
dopamine network contributes to
executive dysfunction
However, dopamine-dependent neural circuitry underlying
executive deﬁcits in Parkinson’s disease may not be limited
to the fronto-striatal network alone. The mesocortical dopa-
mine network originates in the midbrain ventral tegmental
area (A10) and projects diffusely to neocortical areas, par-
ticularly prefrontal, insular and cingulate cortices (Oades
and Halliday, 1987) (Figs 1 and 3). Release of dopamine
from this network modulates prefrontal D2 receptors and
thereby facilitates cognitive ﬂexibility, a core feature of ex-
ecutive processing (Floresco and Magyar, 2006). Insular
cortex in particular is considered to mediate such ﬂexibility,
acting as a hub to recruit other cognitive circuits such as the
fronto-parietal network (Menon and Uddin, 2010). In sup-
port of this, insular lesions in human patients have been
shown to impair performance on tasks requiring cognitive
ﬂexibility (Hodgson et al., 2007).
Post-mortem studies have shown degeneration of the
mesocortical network in Patients with Parkinson’s disease
(Javoy-Agid and Agid, 1980; Scatton et al.,1 9 8 3 ) ,w i t ha
further selective loss of dopaminergic neurons in the lateral
ventral tegmental area speciﬁc to development of PDD (Hall
et al., 2014). In vivo PET imaging studies conﬁrm dopamin-
ergic dysfunction in this network in Parkinson’s disease
(Ouchi et al., 1999; Yagi et al., 2010), with a speciﬁc reduc-
tion of D2 receptor availability in insular cortex occurring in
cognitively impaired patients and correlating closely with
impairment on executive tests (Christopher et al., 2014).
Furthermore, volumetric MRI studies have shown close cor-
relations between atrophy of insular cortex and conversion
to PDD (Melzer et al., 2012; Lee et al., 2013). Therefore,
substantial evidence implicates a concurrent dysfunction in
the mesocortical dopamine network in the pathophysiology
of Parkinson’s disease, with speciﬁc disruption of projections
to insular cortex contributing to worsening executive impair-
ments and PDD, possibly by impairing the ability to recruit
other cognitive networks.
Dysexecutive symptoms may
emerge when inter-network
compensation fails
How dysfunction in the fronto-striatal and mesocortical
dopaminergic networks may interact to cause dysexecutive
symptoms in PDD is unclear. However the results of
Christopher and colleagues (2014) suggest that it is
supervening dysfunction in the mesocortical projections to
the insular upon existing fronto-striatal network disruption
that heralds major executive impairment. Indeed there is
limited evidence suggesting some redundancy between the
two systems in early Parkinson’s disease: in one study
patients performing a set-shifting task did not display
behavioural impairment despite fronto-striatal hypoactiva-
tion on functional MRI, possibly because they displayed
concurrent hyper-activation in the insular and fronto-par-
ietal networks, which was not present in controls (Au et al.,
2012). Using functional MRI, Monchi and colleagues
(2007) also noted a relative increase in blood-oxygen
level-dependent activity within frontal regions in patients
during a matching task. Although this evidence is indirect
it suggests that the mesocortical network may partially
compensate for fronto-striatal dysfunction in early disease,
until it too is damaged, compensation is lost, and a full-
blown dysexecutive syndrome develops. Such a proposal is
compatible with, and extends, the hypothesis proposed by
others that deﬁcient interplay between the fronto-striatal
and mesocortical dopamine networks underlies the dysex-
ecutive syndrome of Parkinson’s disease (Cools, 2006;
Monchi et al., 2004).
Disruptions in non-dopaminergic
brain networks contribute to
executive dysfunction
Levodopa administration does not improve all executive
deﬁcits in PDD (Pillon et al., 1989; Poewe et al., 1991;
Jubault et al., 2009), or even in early Parkinson’s disease
(Lewis et al., 2005; Muslimovic et al., 2005). In fact the
relationship between dopamine replacement and executive
performance is complex (Cools, 2006), in that either too
high or too low levels of prefrontal dopamine are asso-
ciated with poor executive performance, and this may
relate partly to COMT (catechol O-methyltransferase)
genotype (Foltynie et al., 2004b; Williams-Gray et al.,
2007b; Nombela et al., 2014). Furthermore, levodopa
does not restore dysfunctional cognitive network patterns
to normal as it does motor network patterns on either
functional MRI (Jubault et al., 2009), or PET (Huang
et al., 2007). Therefore, it seems likely that impairments
in other brain networks and neurotransmitter systems
also contribute to executive dysfunction in PDD
(Zgaljardic et al., 2004).
The noradrenergic network projecting from the locus
coeruleus to the thalamus, amygdala and cortex (Figs 1
and 3) is also compromised in Parkinson’s disease
(Scatton et al., 1983; Bertrand et al., 1997), with the
extent of neuronal loss in this system correlating with de-
velopment of PDD (Cash et al., 1987; Zweig et al., 1993;
Del Tredici and Braak, 2013). Noradrenalin release in pre-
frontal cortex increases the responsiveness of neurons to
diverse inputs, thereby facilitating cognitive ﬂexibility
(Vazey and Aston-Jones, 2012). Therefore damage to this
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 system in patients with Parkinson’s disease may underlie
deﬁcits in executive functions reliant on cognitive ﬂexibility,
such as rule-shifting, response inhibition and working
memory, and indeed administration of noradrenergic agon-
ists reverses these deﬁcits (Be ´dard et al., 1998; Riekkinen
et al., 1999).
It must also be borne in mind that executive function is
interdependent upon other cognitive faculties, such as the
ability to maintain an alert and attentive state in order to
concentrate on a task. Thus concurrent dysfunction in brain
networks mediating these other functions will also contribute
to the overall level of executive disability. For example, the
nucleus basalis of Meynert (NBM) cholinergic network is
strongly implicated in maintenance of an attentive state (dis-
cussed below), and degenerates signiﬁcantly in PDD leading
to widespread cortical cholinergic dysfunction (Kuhl et al.,
1996; Bohnen et al., 2003; Gratwicke et al., 2013), demon-
strated in vivo by a 30% reduction in cholinergic ligand bind-
ing on PET across all cortical areas, compared to only 10% in
non-demented Parkinson’s disease (Hilker et al., 2005). Close
correlations have been demonstrated between this cortical
cholinergic dysfunction in PDD and worsening scores on
tests of working memory, rule-switching and response inhib-
ition (Bohnen et al., 2006), all of which require a strong at-
tentional component. Therefore this suggests that damage to
the NBM attention network indirectly contributes to the ex-
ecutive dysfunction of PDD.
In summary, executive dysfunction in PDD is a complex
phenomenon, mediated primarily by dysfunction in fronto-
striatal and mesocortical dopaminergic circuitry, but with
interacting inﬂuences from dysfunctional noradrenergic and
cholinergic networks too.
Attention: fronto-parietal,
corticopetal cholinergic and
noradrenergic networks
Attention is a heterogeneous construct that has been con-
sidered to comprise three different subsystems: executive
control, orienting and alerting (Posner and Petersen,
1990; Petersen and Posner, 2012). It has been proposed
that the executive control subsystem allocates attentional
resources to tasks. It is the volitional focusing of attention
and considered to depend on ‘top-down’ signals derived
from knowledge about task demands (Kastner and
Ungerleider, 2000). ‘Orienting’ refers to attention being
drawn to an environmental stimulus for focused cognitive
processing to the exclusion of other stimuli. It is automatic
capture of attention and thought to be driven by ‘bottom-
up’ signals from salient stimuli (Desimone and Duncan,
1995). Alerting is a heightened state of arousal and ‘vigi-
lance’ is the maintenance of this aroused state over time
(Parasuraman, 1998). Vigilance facilitates faster orienting
and reaction time, whereas the opposite state, drowsiness,
will impair these functions.
Attention deﬁcits are detectable in Parkinson’s disease
from an early stage, particularly on tests sensitive to deﬁcits
in executive control such as the digit span, Trail Making
Test Part B, Stroop interference test and attentional set-
shifting tasks (Muslimovic et al., 2005; Williams-Gray
et al., 2008). Non-demented patients also demonstrate im-
paired orienting of visual and auditory attention (Wright
et al., 1990; Sharpe, 1992; Poliakoff et al., 2003). With
progression to PDD these deﬁcits worsen, and impaired
vigilance also develops with ﬂuctuating levels of alertness
(Ballard et al., 2002), which in turn drives ﬂuctuating levels
of cognition (Walker, 2000). Attention deﬁcits are the most
disabling symptom in PDD, predicting worse activities of
daily living and consequent poorer quality of life (Bronnick
et al., 2006). Such deﬁcits are easily identiﬁable in clinic:
patients classically lose their train of thought during a sen-
tence, fail to follow the conversation, or display ﬂuctuant
alertness.
The complex neural networks that mediate attention
functions in the healthy state are subject to ongoing
debate (Petersen and Posner, 2012). Nevertheless, experi-
mental evidence suggests that dysfunction in several distinct
brain networks underlie the deﬁcits in attentional functions
seen in patients with PDD.
Dysfunction in the fronto-parietal
network impairs ‘top-down’
executive control
Volitional shifts of attention are thought to depend on ‘top-
down’ signals within a fronto-parietal network comprising
prefrontal cortical areas and posterior parietal cortices (Figs
2 and 3), wherein prefrontal regions modulate activity in
the network according to task demands (Posner and
Dehaene, 1994; Kastner and Ungerleider, 2000;
Buschman and Miller, 2007).
Imaging studies using ﬂuorodeoxyglucose (FDG)-PET
have shown that patients with both Parkinson’s disease
with mild cognitive impairment (PD-MCI) and PDD dem-
onstrate extensive hypometabolism in frontal and parietal
cortices compared to cognitively normal patients with
Parkinson’s disease (Huang et al., 2007, 2008; Yong
et al., 2007; Hosokai et al., 2009; Liepelt et al., 2009).
In addition, voxel-based morphometric MRI analyses and
diffusion tensor imaging (DTI) studies have shown that pa-
tients with PDD demonstrate extensive grey matter atrophy
and white matter microstructural alterations, respectively
within the above cortical regions (Burton et al., 2004;
Summerﬁeld et al., 2005; Lee et al., 2010; Song et al.,
2011; Hattori et al., 2012; Melzer et al., 2012). To inves-
tigate this relationship, one centre co-registered MRI and
FDG-PET scans in individual patients with cognitively
intact Parkinson’s disease, PD-MCI or PDD, and compared
cortical metabolism and atrophy amongst these cognitive
groups (Gonza ´lez-Redondo et al., 2014). They found that
cognitive decline correlated closely with a progressive
1458 | BRAIN 2015: 138; 1454–1476 J. Gratwicke et al.
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 pattern of sequential hypometabolism followed by atrophy
in both frontal and parietal cortices. Furthermore the spa-
tial pattern of fronto-parietal hypometabolism has been
shown to correlate closely with deﬁcits on a test of execu-
tive control (Trail Making Test Part B), and can be reliably
used to predict test scores in other cognitively impaired
patients (Huang et al., 2007). Therefore, these studies high-
light a progressive degeneration in frontal and parietal cor-
tices in the development of PDD, which correlates closely
with deﬁcits in the executive control of attention.
In Alzheimer’s disease it has been shown that atrophy in
speciﬁc cortical regions damages structural connections and
leads to loss of functional connectivity within brain net-
works (He et al., 2007). Given the extensive atrophy
within frontal and parietal cortices seen in PDD then the
same may hold true for the fronto-parietal network, and
indeed functional imaging evidence supports this.
Functional MRI studies show that non-demented
Parkinson’s patients activate the fronto-parietal network
while performing attentional set-shifting tasks (Williams-
Gray et al., 2008); however, activation of the network
during such volitional shifts of attention is not as strong
as in control subjects due to reduced connectivity within
prefrontal cortical regions (Rowe et al., 2002). With
progression to PDD there is evidence of a further reduction
in connectivity within the network compared to non-
demented patients. Investigators in one centre scanned
both patients with Parkinson’s disease and PDD with
MEG (magnetoencephalography) in the resting state and
compared cortical oscillatory activity (Ponsen et al.,
2012). They found that patients with PDD demonstrated
both a relative decrease in beta oscillatory power in the
frontal cortices and reduced functional connectivity across
cortical regions in the beta frequency band. In the healthy
state it has been shown that an increase in beta-band syn-
chrony within the fronto-parietal network drives the execu-
tive control of attention (Buschman and Miller, 2007).
Therefore, this relative decrease in fronto-parietal
Figure 2 The major cortical neural networks affected in PDD. Areas of cortical atrophy associated with visuospatial and visuoperceptual
deﬁcits in PDD (coloured green and purple, respectively) are based on the data presented in Pereira et al. (2009). Areas of cortical atrophy
speciﬁcally associated with the presence of visual hallucinations in PDD (coloured blue) are based on the data presented in Goldman et al. (2014a).
Functional cortical regions comprising the fronto-parietal attention network (highlighted red) are based on the data presented in Williams-Gray
et al. (2008). Cortical regions are identiﬁed according to the Allen Brain Atlas for the human brain, and manually drawn onto the corresponding
3D brain image. In this representation the same cortical regions are affected symmetrically in both hemispheres, however in the original studies
above the extent of atrophy in these regions was not symmetrical between hemispheres, and varied between individual patients. In the inferior
view of the cortex the cerebellum has been removed to expose the fusiform gyri more clearly. DLPFC = dorsolateral prefrontal cortex;
PPC = posterior parietal cortex; VLPFC = ventrolateral prefrontal cortex.
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 beta-band connectivity in PDD may represent the func-
tional mechanism underlying impairment in this mode of
attention.
Therefore, substantial structural and functional evidence
exists to support the hypothesis that dysfunction in the
fronto-parietal network impairs top-down control of atten-
tion in PDD. However, future studies directly exploring the
contribution of cortical structural changes to functional
connectivity and relating this to attentional impairments
in PDD are needed to conﬁrm these observations.
Furthermore, the contribution of different neurotransmit-
ters to fronto-parietal network dysfunction remains to be
elucidated. Patients with Parkinson’s disease with low
activity COMT genotypes (who have higher cortical dopa-
mine levels) appear to under-activate the fronto-parietal net-
work with consequent poorer performance on set-shifting
tasks (Williams-Gray et al., 2008), while the pattern of
cortical atrophy seen within the network in PDD correlates
closely with areas showing cholinergic hypofunction on
PET imaging (Hilker et al., 2005).
Dysfunction in cholinergic and
noradrenergic networks impairs
‘bottom-up’ orienting of attention
One view of automatic orienting of attention considers it to
be mediated by ‘bottom-up’ or stimulus-driven signals from
the NBM in the basal forebrain (Sarter et al., 2005). This
nucleus consists of 90% cholinergic neurons and its’ wide-
spread projection axons provide the main cholinergic in-
nervation to the entire cortical mantle (‘corticopetal’
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Figure 3 Hypothetical model of the neural networks affected in PDD and corresponding cognitive deﬁcits. Solid arrows
correspond to direct neural connections and colours are indicative of the primary neurotransmitter involved as shown in the key. Dashed arrows
connect the relevant dysfunctional neural network to its putative cognitive effects. Purple arrows indicate that a deﬁcit in one cognitive domain
contributes to the development of impairment in another domain. Black crosses indicate damage to a neural pathway. The red dashed arrow
represents direct projections from prefrontal cortex to the NBM, permitting top-down control of attention from the fronto-parietal network via
recruitment of this latter structure and its cortical projections. The limbic, orbitofrontal and associative circuits in the prefrontal cortex
correspond to the dissociable fronto-striatal loops of Alexander et al. (1986). Note effects of levodopa therapy at improving and worsening
executive functions reliant on cognitive ﬂexibility and learning from feedback, respectively. Electrocortical activation refers to cortical EEG
desynchonization indicative of the awake/alert state as described in the text, and is driven by corticopetal cholinergic input from the NBM only.
Both cholinergic input from NBM and noradrenergic input from the locus ceruleus (LC) modulate processing in sensory cortices to facilitate
orienting of attention to stimuli. Cx = cortex; DLPFC = dorsolateral prefrontal cortex; fx = function; GPi = globus pallidus (internus);
PPC = posterior parietal cortex; SNpc = substantia nigra pars compacta; VLPFC = ventrolateral prefrontal cortex; VTA = ventral tegmental area.
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 innervation) (Mesulam et al., 1983; Mufson et al., 2003;
Gratwicke et al., 2013) (Figs 1 and 3). Selective activation
of the nucleus basalis of Meynert (NBM) network causes
an increase in acetylcholine levels in the cortical target ﬁeld,
which boosts the signal-to-noise ratio for salient stimuli,
thereby enhancing the strength of their neural representa-
tions (Goard and Dan, 2009; Bentley et al., 2011; Pinto
et al., 2013; Soma et al., 2013). In facilitating this process
the NBM effectively ampliﬁes detection of salient stimuli by
posterior regions of the fronto-parietal network and en-
sures their attentional signiﬁcance (Sarter et al., 2006;
Buschman and Miller, 2007). Animal experiments have
shown that this NBM-driven cortical signal enhancement
is responsible for generating event-related potentials
(ERPs) on the EEG (Nguyen and Lin, 2014). These can
be measured on the human EEG as negative deﬂections
occurring 80–100ms after an unpredictable stimulus (the
N1 ERP), and have long been regarded as the electro-
physiological correlate of orienting of attention (Hillyard
et al., 1973).
The NBM degenerates in Parkinson’s disease, with human
neuropathological series showing 32% cell loss in non-de-
mented patients, rising to 54–70% in PDD, which is closely
associated with increasing cortical cholinergic deﬁcits and
worsening cognitive impairment (Whitehouse et al.,1 9 8 3 ;
Gaspar and Gray, 1984; Perry et al., 1985; Hall et al.,
2014). This is supported by both volumetric MRI and
PET imaging studies, which demonstrate signiﬁcant NBM
atrophy and cortical cholinergic binding reductions, respect-
ively in patients with PDD compared to both cognitively
intact Parkinson’s disease patients and control subjects
(Hanyu et al., 2002; Hilker et al., 2005; Bohnen et al.,
2006; Shimada et al., 2009; Choi et al., 2012). This disrup-
tion of NBM cholinergic input to cortex attenuates cortical
signal processing (Pinto et al., 2013), which is demonstrated
by the fact that patients with PDD performing orienting of
attention tasks display increased N1 event-related potential
latencies compared to both non-demented patients and con-
trols, which correlate with behavioural errors (Goodin and
Aminoff, 1987; Hautecoeur et al., 1991; Stam et al., 1993).
Therefore, disruption of bottom-up signal enhancement in
the NBM network appears to underlie the deﬁcits in orient-
ing seen in PDD.
Interestingly, direct prefrontal cortical projections to the
NBM may modulate activity of its cholinergic inputs to
sensory cortices and has been suggested to represent a com-
ponent of the top-down fronto-parietal attention network
(Sarter et al., 2005). Thus depending on the type of stimu-
lus and task characteristics, activity in the NBM network
may reﬂect the combined effects of top-down and bottom-
up modes of attention (Bentley et al., 2004; Sarter et al.,
2006), meaning that degeneration in this network in PDD
may play a key role not only in orienting deﬁcits but in
deﬁcits in executive control of attention as well (Fig. 3).
Finally, the ascending noradrenergic network is also
implicated in orienting of attention (Aston-Jones et al.,
1999) and, as described above, this network degenerates
progressively in PDD. Administration of the selective
alpha-1 noradrenergic agonist naphtoxazine to patients
with PD-MCI improves performance on an orienting of
attention task accompanied by improved lateralization of
the N1 event-related potential (Be ´dard et al., 1998). This
suggests that lack of bottom-up noradrenergic input from
the locus coeruleus may also play a role in orienting deﬁcits
in PDD; however, its interaction with the cholinergic
system and their relative contributions remain unclear.
Slowed cortical rhythms on the
EEG reﬂect impaired vigilance and
underlie cognitive ﬂuctuation
As mentioned above the onset of impaired vigilance and
ﬂuctuating attention/cognition is particularly characteristic
of progression to PDD (Emre et al., 2007). In tandem with
its role in enhancing processing of salient stimuli, the NBM
cholinergic network also plays a key role in the ascending
arousal network. The NBM receives noradrenergic afferents
from the locus coeruleus (Fig. 1) and glutamatergic affer-
ents from the reticular formation and acts as an extra-
thalamic relay to the cortex and limbic system
(Szymusiak, 1995; Jones, 2004). Its cholinergic projections
can directly desynchronize the neocortical EEG, replacing
slow synchronized delta waves (0.5–4Hz, indicative
of the non-aroused state) with fast beta and gamma
waves (13–30 and 30+ Hz, respectively, indicative of arou-
sal) (Metherate et al., 1992; Lee et al., 2005; Kalmbach
et al., 2012).
Awake EEG studies in patients with PDD have consist-
ently shown an increase in slow delta wave activity across
the cortex, with a progressive gradient of increasing delta
wave activity seen when comparing cognitively intact
patients with Parkinson’s disease, patients with PD-MCI
and PDD (Soikkeli et al., 1991; Neufeld et al., 1994;
Caviness et al., 2007). In agreement with this resting
state, MEG studies have also shown a relative increase
in cortical delta oscillatory power in patients with PDD
compared to non-demented Parkinson’s disease, alongside
a relative decrease in faster beta and gamma
activity (Bosboom et al., 2006; Ponsen et al., 2012).
Administration of the acetylcholinesterase inhibitor
(AChEI) rivastigmine to patients with PDD undergoing
MEG returns these slowed cortical rhythms to normal
(Bosboom et al., 2009). This therefore supports the hypoth-
esis that dysfunction in the NBM cholinergic network
underlies the electrocortical depression characteristic
of PDD. Rodents with NBM lesions have similar
slow delta activity on the EEG and concurrently display
reduced arousal or coma (Buzsaki et al., 1988; Fuller
et al., 2011). Therefore, NBM cholinergic dysfunction
leading to progressive electrocortical depression in PDD
may represent the pathophysiological correlate of impaired
vigilance (Fig. 3).
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 In addition, Bonanni et al. (2008) have shown that pa-
tients with PDD with signiﬁcant cognitive ﬂuctuations (mea-
sured by the Clinician Assessment of Fluctuation Scale)
demonstrate pseudocyclic patterns of slow wave activity on
the EEG in the delta-theta-pre-alpha range (1–7.9Hz),
whereas patients with PDD without ﬂuctuations do not
(Bonanni et al., 2008). This therefore implies that develop-
ment of slow EEG rhythms cycling between relatively greater
and lesser states of cortical arousal may represent the patho-
physiological basis of cognitive ﬂuctuation in PDD.
However, further work is needed to establish the mechan-
isms underlying generation of such rhythms, and why some
patients with PDD develop them while others do not.
Memory: medial temporal
lobe and corticopetal
cholinergic networks
Memory is an all-encompassing term for the cognitive pro-
cesses involved in the encoding, storage and retrieval of
information. As with the other cognitive domains it is not
a pure process, and is interdependent upon a person being
able to orient attention to a stimulus (to allow encoding),
and use executive processes to allow retrieval in a particu-
lar context. As discussed above, patients with Parkinson’s
disease and PDD exhibit deﬁcits in each of these latter
processes, which means that apparent memory impairments
have a multifactorial basis here. For example, patients with
Parkinson’s disease exhibit impaired free recall (spontan-
eous retrieval) but beneﬁt substantially from cueing,
demonstrating that externally triggered retrieval is intact
(Lees and Smith, 1983; Costa et al., 2014). Recognition
memory is also intact at this stage (Lees and Smith,
1983; Taylor et al., 1986) although there is some debate
about this (Whittington et al., 2000). Overall, this indicates
that memories are encoded and stored, but not independ-
ently retrieved. Performance on free recall in this group is
signiﬁcantly predicted by scores on executive tests, indicat-
ing that executive dysfunction contributes to retrieval
failure (deﬁcient internal search strategies), and is respon-
sible for the apparent mnemonic deﬁcit rather than a
dysfunction of storage (Pillon et al., 1993; Costa et al.,
2014). This contrasts with Alzheimer’s disease where both
recall and recognition are equally impaired from early on,
implicating a temporal-limbic storage deﬁcit (Helkala et al.,
1988; Pillon et al., 1993).
With progression from Parkinson’s disease to PDD, how-
ever, both a cross-sectional study and a meta-analysis have
shown that difﬁculties with recognition memory also
become apparent, implicating a supervening dysfunction
of temporal lobe storage mechanisms upon pre-existing
executive retrieval deﬁcits when patients convert to demen-
tia (Whittington et al., 2000, 2006). This is supported by
data showing that patients with PDD exhibit signiﬁcant
impairments with confrontation naming (a test of visual
recognition memory) and greater deﬁcits in semantic than
phonemic verbal ﬂuency (both require efﬁcient executive
retrieval but the former has a greater dependence on tem-
poral lobe storage) (Henry and Crawford, 2004). Both con-
frontation naming and semantic verbal ﬂuency are
dependent on semantic information (previously learnt gen-
eral factual information) (Tulving, 1972) and therefore
these tests are relatively resistant to attentional impairments
since encoding of such information would have taken place
in the pre-morbid state. Therefore, it seems likely that
a true mnemonic storage deﬁcit is present in PDD in
addition to the problems with deﬁcient attention/encoding
and poor executive retrieval that manifest earlier in
Parkinson’s disease.
In the clinic, problems with memory are one of the most
frequent non-motor symptoms reported by both patients
and carers (Breen and Drutyte, 2013). However, the differ-
entiation between apparent memory deﬁcits due to atten-
tional or executive impairments, and ‘true’ temporal-limbic
storage deﬁcits is not evident from the patients’ self-re-
ported memory complaints, and this requires detailed ques-
tioning or cognitive testing to delineate.
Atrophy within the medial temporal
lobe network correlates with
progression to Parkinson’s disease
dementia
Medial temporal lobe structures (hippocampus, parahippo-
campus, entorhinal and perirhinal cortices and amygdala)
(Fig. 3) are involved in memory storage and retrieval
(Squire et al., 2004; Lech and Suchan, 2013), and patients
with Parkinson’s disease demonstrate hypoactivation of
these structures during visual memory tasks from the
point of diagnosis (although mnemonic deﬁcits are subclin-
ical at this time) (Nombela et al., 2014). However, previous
volumetric MRI studies have provided conﬂicting results as
to whether signiﬁcant MTL atrophy occurs in PDD
(Camicioli et al., 2003; Junque ´ et al., 2005; Tam et al.,
2005; Ibarretxe-Bilbao et al., 2008). These discrepancies
are likely due to the differing criteria for dementia used,
and the fact that results were not co-varied by motor scores
to determine atrophy speciﬁc to cognitive decline. To
address these issues, a recent study used the MDS
(Movement Disorders Society) Task Force Criteria for
PDD (Emre et al., 2007) and recent criteria for PD-MCI
(Dalrymple-Alford et al., 2011) to select representative
patient groups for voxel-based morphometry MRI analysis
(Melzer et al., 2012). Having adjusted results by individual
UPDRS (Uniﬁed Parkinson’s Disease Rating Scale, part III)
motor scores they showed that cognitive progression from
Parkinson’s disease to PD-MCI to PDD speciﬁcally corre-
lated with increasing grey matter atrophy in MTL struc-
tures including the hippocampi, parahippocampi and
amygdalae. A recent meta-analysis of six voxel-based
morphometry MRI studies involving a total of 105 patients
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 with PDD and 131 control subjects conﬁrms this (Pan
et al., 2013).
Although these data conﬁrm that progression to PDD is
associated with worsening MTL atrophy, further studies
are needed to speciﬁcally demonstrate a link between
damage to this network and worsening memory storage
deﬁcits (assessed by decline on tests of recognition or
semantic memory). At present we can only hypothesize
that this is the case based on the known functional anat-
omy of the MTL network (Squire et al., 2004).
Dysfunction of the nucleus basalis of
Meynert cholinergic network impairs
encoding of memories
Aside from its role in orienting of attention, the NBM cho-
linergic network has also been implicated in memory
encoding. The release of acetylcholine from its end ter-
minals has been shown to induce plastic reorganization of
cortical receptive ﬁeld maps, representing the putative
encoding of a ‘physiological memory’ (Bakin and
Weinberger, 1996; Kilgard and Merzenich, 1998; McLin
et al., 2002). Simultaneously, as described above, this trans-
mitter release directly desynchronizes the neocortical EEG
by inducing fast gamma, beta and theta oscillations (Lee
et al., 2005; Kalmbach et al., 2012), and evidence suggests
that phase-coupling of these oscillations between cortical
and MTL regions is necessary for memory encoding in
humans (Huerta and Lisman, 1993; Fell and Axmacher,
2011; Lee et al., 2013). Conversely NBM lesions in animals
have been shown to block this electrocortical activation
(Buzsaki et al., 1988; Fuller et al., 2011), and cause impair-
ments of learning and memory (Bartus et al., 1985; Mandel
et al., 1989; Butt and Hodge, 1995; Leanza et al., 1996), as
well as impairments in orienting of attention (Voytko et al.,
1994; Voytko, 1996).
As described in the previous section, the NBM choliner-
gic network degenerates signiﬁcantly in PDD with up to
70% cell loss (Whitehouse et al., 1983), which correlates
with progressive electrocortical depression on MEG
(Bosboom et al., 2006; Ponsen et al., 2012). Therefore,
we hypothesize that dysfunction in this network impairs
both orienting of attention to a stimulus and (in conjunc-
tion with dysfunction in the MTL network) the induction
of electrocortical synchrony necessary for the successful
encoding of that stimulus into memory (Fig. 3). Further
electrophysiological studies in patients with PDD are
needed to investigate this further; however, it is not surpris-
ing that dysfunction of the NBM cholinergic network is
implicated in both attention and memory deﬁcits as
neuroimaging and computational studies in healthy
humans suggest that cholinergic enhancement of cor-
tical signal detection (orienting of attention) facilitates for-
mation of novel input associations (memory encoding)
(Hasselmo and McGaughy, 2004; Bentley et al., 2009).
Thus these cognitive functions are interrelated and are
actually part of a continuous process for recording salient
environmental stimuli into memory (Sarter et al., 2003).
Visual perceptual dysfunction
and hallucinations: multiple
network involvement
Patients with Parkinson’s disease exhibit both subtle visuo-
spatial deﬁcits (difﬁculties with the perception of extra-
personal space) (Lee et al., 1998; Levin et al., 1991;
Montse et al., 2001), and visuoperceptive deﬁcits (difﬁcul-
ties recognizing objects based on their form) (Villardita
et al., 1982; Laatu et al., 2004; Kida et al., 2007), in
some patients from early in the disease (Foltynie et al.,
2004a). These deﬁcits become more marked and more
common with disease progression (Levin et al., 1991) and
show high sensitivity in detecting the transition to PDD
(Zgaljardic et al., 2004; Kehagia et al., 2010; Biundo
et al., 2014). Indeed impairment on the Pentagon
Copying Test from the MMSE at baseline has been
shown to be predictive of PDD at 5-year follow-up
(Williams-Gray et al., 2009).
Visual hallucinations are also well-recognized in
Parkinson’s disease and are typically complex, consisting
of well-formed people, animals or objects (Barnes and
David, 2001). Although they can be induced by anti-
parkinsonian drugs, correlations between use of these
agents and presence of hallucinations are actually relatively
weak, and instead cognitive impairment has been shown to
be the major risk factor, indicating that they are a core
symptom of the dementing process (Fe ´nelon et al., 2000;
Williams and Lees, 2005). Visual hallucinations generally
occur in the latter stages of the disease course with a pro-
gressive nature (Goetz et al., 2001; Williams and Lees,
2005). Their presence is a strong predictor of PDD
(Galvin et al., 2006; Santangelo et al., 2007) and indeed
the prevalence of hallucinations in PDD is 70% (Fe ´nelon
et al., 2000). Although insight is initially maintained in
patients with PDD, 81% will lose insight over 3 years
(Fe ´nelon et al., 2000; Goetz et al., 2006), which severely
affects quality of life for both patients and caregivers
(Goetz and Stebbins, 1993; Aarsland et al., 2000).
Visual perceptual dysfunction
correlates with atrophy in posterior
visual cortices
Only one study has speciﬁcally looked at in vivo neuroana-
tomical correlates of visual perceptual dysfunction in PDD.
Using voxel-based morphometry MRI analysis, Pereira and
colleagues (2009) showed that PD-MCI patients have
greater grey matter atrophy in both occipito-temporal and
dorsal parietal cortices compared to controls, and that
these patterns correlated with impairments on tests of
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 visuoperceptual and visuospatial abilities, respectively
(Pereira et al., 2009) (Fig. 2). These correlations agree
with the dual-stream hypothesis of visual processing,
wherein the dorsal stream from the occipital to the parietal
lobe processes spatial location while the ventral stream
from occipital lobe to temporal and limbic structures pro-
cesses object recognition (Ungerleider and Mishkin, 1982).
Indeed functional imaging in patients with Parkinson’s dis-
ease performing visuospatial tasks shows reduced parietal
activation which correlates with increasing errors (Nombela
et al., 2014). The above patterns of cortical atrophy show
spatial congruence with areas showing signiﬁcant hypome-
tabolism and cholinergic deﬁcits in patients with PDD,
in-line with deafferentation from the NBM network
(Hilker et al., 2005; Klein et al., 2010). This is supported
by DTI studies which demonstrate signiﬁcant white matter
microstructural alterations in bilateral posterior cingulate
bundles in patients with PDD compared to non-demented
Parkinson’s disease (Matsui et al., 2007), the same ﬁbre
tracts through which cholinergic projections from NBM
to visual cortices travel (Gratwicke et al., 2013). As
bottom-up NBM cholinergic input is known to enhance
visual cortical responses and thereby improve visual dis-
crimination ability (Bhattacharyya et al., 2013; Pinto
et al., 2013; Soma et al., 2013), dysfunction in this network
due to NBM degeneration may underlie the visual percep-
tual dysfunction seen in PDD (Fig. 3).
Independent dysfunction in posterior
visual processing networks underlies
visual hallucinations
The mechanism underlying the generation of visual hallucin-
ations in PDD is more complex and likely represents inter-
acting dysfunction between several different brain networks.
Since the presence of hallucinations is closely correlated with
visuospatial and visuoperceptual deﬁcits in PDD (Ramı ´rez-
Ruiz et al., 2006; Sinforiani et al., 2006), dysfunction in
associative visual cortices within the dorsal and ventral pro-
cessing streams has long been implicated in their generation.
This is supported by neuropathological studies which have
demonstrated strong correlations between Lewy body
burden in parietal and temporal lobes (particularly limbic
structures) and the presence of hallucinations in PDD
(Harding et al., 2002; Papapetropoulos et al.,2 0 0 6 ;
Kalaitzakis et al., 2009; Gallagher et al., 2011).
Nevertheless, MRI studies comparing brain atrophy patterns
between patients with Parkinson’s disease with and without
visual hallucinations have not consistently supported these
pathological associations, differentially implicating medial
temporal (Ibarretxe-Bilbao et al., 2008, 2010; Shin et al.,
2012), insular (Shine et al., 2014), pedunculopontine nucleus
(Janzen et al., 2012) and frontal atrophy (Ibarretxe-Bilbao
et al., 2010; Sanchez-Castaneda et al., 2010). All may play a
part in generation of hallucinations; however, the degree of
cognitive impairment between patients with and without
hallucinations was not controlled for in these studies, mean-
ing that atrophy patterns may have related to cognitive dif-
ferences rather than the presence of hallucinations per se.I n
addition, the use of differing classiﬁcation criteria for PDD
[including MMSE 524, Diagnostic Statistical Manual
(DSM) IV-TR or Movement Disorders Society Task Force
criteria] further complicates interpretation of these results.
A recent study overcame these problems, by using
Movement Disorders Society criteria to select patients
with PDD with and without visual hallucinations and
ensured they were matched for antiparkinsonian medica-
tions, global cognitive decline and scores on all cognitive
subdomains, including visuoperceptual impairments
(Goldman et al., 2014a). Structural MRI scans from both
groups were analysed using voxel-based morphometry,
then compared. PDD hallucinators exhibited signiﬁcant
grey matter atrophy in the cuneus, lingual and fusiform
gyri, middle occipital lobe and inferior parietal lobule com-
pared to non-hallucinators (Figs 2 and 3). These results
seem to conﬁrm that discrete areas of atrophy in the pos-
terior visual processing networks speciﬁcally underlie the
generation of hallucinations in PDD, and thereby provide
an in vivo correlate to neuropathological data. Of note,
these atrophy patterns were independent of visuoperceptual
impairments, suggesting that generation of visual hallucin-
ations in PDD does not merely represent a progression of
such impairments but is instead dependent on different
mechanisms.
Functional neuroimaging studies provide further evidence
that dysfunction in posterior visual processing networks
underlies generation of visual hallucinations in PDD.
Resting state SPECT (single-positron emission computed
tomography) and FDG-PET studies have shown decreased
perfusion and metabolic rates, respectively in posterior
visual cortices in patients with Parkinson’s disease with
hallucinations compared to those without (Oishi et al.,
2005; Matsui et al., 2006; Boecker et al., 2007).
Furthermore, functional MRI studies during visual stimula-
tion paradigms have demonstrated hypoactivation of pos-
terior visual areas in patients with Parkinson’s disease with
hallucinations in comparison to those without (Stebbins
et al., 2004; Meppelink et al., 2009).
Thus recent structural and functional neuroimaging evi-
dence supports earlier neuropathological data and indicates
that speciﬁc damage to posterior visual processing net-
works in PDD contributes to the generation of hallucin-
ations. The exact pathophysiological process responsible
remains to be shown deﬁnitively. However, these dysfunc-
tional visual regions again show signiﬁcant congruence
with areas of cholinergic deafferentation as described
above, indicating that loss of cortical input from the
NBM network in PDD could underlie aberrant processing
in visual cortices and thereby contribute to generation of
hallucinations. This is supported by clinical trial data show-
ing that treatment of patients with PDD with the mixed
AChEI/nicotinic acetylcholine receptor agonist galantamine
can markedly reduce hallucinations (Litvinenko et al.,
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 2008). Because NBM activation alters cortical acetylcholine
levels and thereby enhances neuronal signal-to-noise ratios
(Goard and Dan, 2009; Pinto et al., 2013; Soma et al.,
2013) then damage to this network in PDD could decrease
the signal-to-noise ratio of salient stimuli, thereby allowing
irrelevant intrinsic and sensory information that would nor-
mally be suppressed to enter perceptual awareness in the
form of hallucinations (Perry and Perry, 1995).
Concomitant dysfunction in frontal
and arousal networks contributes to
generation of visual hallucinations
Overlapping dysfunctions in a number of other cognitive
networks are also likely to contribute to the generation of
visual hallucinations in PDD. For example, several functional
MRI studies comparing patients with Parkinson’s disease
with hallucinations to those without during performance of
visual paradigms have demonstrated not only dysfunction in
visual cortical areas in the former, but also simultaneous
disruption of activity in frontal areas (Stebbins et al.,
2004; Meppelink et al., 2009; Shine et al., 2014). The pres-
ence of hallucinations in PDD is closely associated with
worsening impairments on tests of attentional control
(Meppelink et al., 2008; Bronnick et al., 2011), as well as
impairments on tests of inhibitory control such as the Stroop
Test and Go/No-Go Task (Barnes and Boubert, 2008), def-
icits that might in part be attributable to dysfunctions in the
fronto-parietal and noradrenergic networks respectively (as
described above). This therefore suggests that breakdown in
these frontal networks may play a contributory role in the
generation of visual hallucinations in PDD, perhaps by redu-
cing attentional and inhibitory control of perceptual errors
arising from dysfunction in posterior visual cortices, allow-
ing them to enter conscious perception as hallucinations
(Shine et al., 2011) (Fig. 3).
In addition, disrupted sleep-wake cycling and REM
(rapid eye movement) sleep behavioural disorder are also
strongly associated with the presence of visual hallucin-
ations in Parkinson’s disease (Nomura et al., 2003;
Whitehead et al., 2008), and intrusion of episodes of
REM sleep during wakefulness is proposed to contribute
to generation of hallucinations (Diederich et al., 2005).
Control of both arousal and REM sleep appears to be
regulated by the NBM (Lee et al., 2005, and as discussed
above) and therefore dysfunction in this network may con-
tribute to generation of visual hallucinations in PDD not
only by disrupting visual perception as above, but also by
deregulating arousal mechanisms.
Overall, therefore, concomitant dysfunction in a number
of brain networks involved in visual perception, inhibitory
control and arousal may all play a role in the generation of
visual hallucinations in PDD, which is supported by clinical
data indicating that the strongest determinants of hallucin-
ations in Parkinson’s disease are impairments of visuoper-
ceptual and frontal functions combined with the presence
of REM sleep behavioural disorder (Gallagher et al., 2011).
However, the relative contributions of these network
dysfunctions and how they interact to produce visual hal-
lucinations remains unclear, and further studies are needed
to examine this.
Relation of the neural
network perspective to
the neuropathology of
Parkinson’s disease dementia
Attheneuropathologicalleveltheconsensusfrom most studies
todateisthattheamountofLewy-relatedpathology(including
LewybodiesandLewyneurites)inneocorticalandlimbicareas
is the most important factor in the development of PDD
(Hurtig et al., 2000; Apaydin et al., 2002; Sabbagh et al.,
2009; Kempster et al., 2010; Irwin et al., 2012; see Halliday
et al., 2014 for review). However, the signiﬁcance of Lewy-
related pathology occurrence in particular cortical areas is
debated, for example one retrospective autopsy study found
that severity of cognitive decline in PDD correlated with
Lewy-related pathology in the frontal and cingulate gyri
(Mattila et al., 2000), while another found no signiﬁcant cor-
relations in these regions but did ﬁnd one in relation to tem-
poral lobe Lewy-related pathology (Harding and Halliday,
2001). Meanwhile some patients with Parkinson’s disease
with cortical Lewy-related pathology do not develop dementia
atall(Colosimoetal.,2003;Kempsteret al.,2010;Irwinetal.,
2012). The signiﬁcance of concurrent Alzheimer-type pathol-
ogies (senile plaques and neuroﬁbrillary tangles) is hotly
debated (Mattila et al., 1998; Apaydin et al., 2002; Hely
et al., 2008; Sabbagh et al., 2009), although a recent study
quantitatively assessing cortical Lewy-related pathology and
Alzheimer-type pathologies found that a combination of both
correlated most robustly with development of PDD (Compta
et al., 2011). The relative contributions of other pathologies
including microvascular disease, cerebral amyloid angiopathy,
argyrophilic grains and TARDBP (previously known as TDP-
43) remain unclear (Del Tredici and Braak, 2013; Halliday
et al., 2014).
Despite the heterogeneity described above, speciﬁc elements
of the neuropathology of PDD do bear a direct relationship
to the dysfunctional neural networks perspective we describe.
For example, the well-documented alpha-synuclein pathology
affecting substantia nigra pars compacta neurons projecting
to the striatum (Gibb and Lees, 1991; Braak et al., 2003) not
only underlies dopamineric loss leading to the movement
symptoms of Parkinson’s disease but also dopaminergic loss
in the frontostriatal network leading to dysexecutive symp-
toms (as discussed above). There is also well-documented
evidence of early Lewy-related pathology in the midbrain
ventral tegmental area and locus coeruleus (Braak et al.,
2003), which underlie the extensive degeneration in the
mesocortical dopaminergic and noradrenergic networks
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 speciﬁc to PDD, respectively (Cash et al., 1987; Del Tredici
and Braak, 2013; Hall et al., 2014), thereby contributing to
deﬁcits in executive function and orienting of attention.
Meanwhile, Lewy-related pathology has been shown to de-
velop in the NBM from the early stages of Parkinson’s dis-
ease (Braak stage 3, Braak et al., 2003), and increasing
alpha-synuclein burden in this structure correlates with
increasing cell loss and the development of PDD (Hall
et al., 2014), thereby underlying the cholinergic dysfunction
which impacts across all cognitive domains as detailed above.
Several neuropathological series have shown signiﬁcantly
higher densities of Lewy-related pathology and amyloid-b
senile plaques in the hippocampi of patients with PDD
compared to non-demented Parkinson’s disease (Irwin
et al., 2012; Hall et al., 2014), which potentially drives
the atrophy of MTL regions speciﬁc to PDD, and may
consequently underlie mnemonic deﬁcits. Interestingly one
study also demonstrated a signiﬁcant reduction of cholin-
ergic innervation to the hippocampus speciﬁc to PDD (Hall
et al., 2014), indicating one way in which combined dys-
function in both the NBM and MTL networks may interact
to cause memory impairments.
Finally, as mentioned above, strong correlations have
been demonstrated between Lewy-related pathology
burden in frontal, parietal and temporo-limbic cortices
and the presence of visual hallucinations in PDD
(Harding et al., 2002; Papapetropoulos et al., 2006;
Kalaitzakis et al., 2009; Gallagher et al., 2011). These pat-
terns of Lewy-related pathology deposition correspond to
the areas of frontal hypofunction and parietal and limbic
cortical atrophy in PDD described above, and therefore
represent the potential neuropathological basis for deﬁcits
in the executive control of attention and visual perception,
respectively, which in combination contribute to generation
of visual hallucinations.
Thus, although there is variation in the overall distribu-
tion and type of cellular neuropathology underlying PDD,
pathological changes at key cognitive nodes display a rela-
tive consistency, and support the neural network model of
PDD. Our model is therefore complementary to the estab-
lished neuropathological basis of PDD, and indeed builds
upon it by providing a functional mechanism.
Implications of the neural
network perspective of
Parkinson’s disease dementia
for clinical practice
Prognostic factors for development of
Parkinson’s disease dementia
In the clinic the diagnosis of PDD is based upon the
Movement Disorders Society Task Force criteria (Dubois
et al., 2007; Emre et al., 2007), which incorporates detec-
tion of the cognitive features described above. However, it
is recognized that early identiﬁcation of patients at risk of
developing PDD is useful in order to monitor them more
closely so that therapeutic and supportive strategies can be
implemented at a stage of the disease when they are likely
to have greatest efﬁcacy. Detailed neuropsychological test-
ing, although able to detect early subclinical deﬁcits, is not
widely available, and therefore identiﬁcation of clinical
features with high predictive value for PDD has pragmatic
value for clinicians. Large longitudinal cohort studies have
demonstrated that inability to copy the intersecting penta-
gons ﬁgure on the MMSE, impairments of semantic verbal
ﬂuency and recognition memory, and development of a
postural instability and gait difﬁculty (PIGD) motor pheno-
type (whether at baseline or later) are signiﬁcant predictors
for PDD (Levy et al., 2002a; Alves et al., 2006; Burn,
2006; Williams-Gray et al., 2007a, 2013; Hely et al.,
2008). Errors on the Pill Questionnaire (in which patients
are asked to describe their medication regime and its time
schedule) and presence of REM sleep behavioural disorder
are also associated with later development of PDD, al-
though their positive predictive values are lower (Postuma
et al., 2012; Martinez-Martin, 2013).
It is interesting to note that all of these predictive clinical
features have a strong putative cholinergic basis according
to the neural network model described above; deﬁcits on
pentagon copying are due to visual perceptive dysfunction
while impairments in semantic verbal ﬂuency and recogni-
tion memory are due to deﬁcits in memory encoding and
temporo-limbic storage, and dysfunction in the NBM net-
work contributes to all of these. The Pill Questionnaire
requires cued recall that probes semantic memory, while
REM sleep behavioural disorder is caused by deregulation
of brainstem arousal networks including the NBM.
Meanwhile motor symptoms of postural instability and
gait difﬁculty in Parkinson’s disease are attributed to dys-
function in a brainstem cholinergic nucleus, the pedunculo-
pontine nucleus (Fling et al., 2013). The pedunculopontine
nucleus has a strong anatomical connection with the NBM
(Pahapill and Lozano, 2000; Gratwicke et al., 2013), and
possibly a functional connection since deep brain stimula-
tion of the pedunculopontine nucleus appeared to improve
attention, memory and visuospatial abilities in a patient
with PDD (Ricciardi et al., 2014). Therefore development
of postural instability and gait difﬁculty might represent a
marker of underlying cholinergic dysfunction that will
affect both circuits. Overall, the predominance of underly-
ing cholinergic dysfunction in the clinical predictors of
PDD highlights the relative importance of damage to this
network above others in its pathogenesis, a theory that is
supported by our proposed neural network model because
the NBM system is implicated across all cognitive impair-
ments of PDD. This agrees with the ‘dual-syndrome hy-
pothesis’, which proposes that while cognitive deﬁcits in
early Parkinson’s disease are mainly mediated by dysfunc-
tion in the fronto-striatal dopamine network, the onset of
1466 | BRAIN 2015: 138; 1454–1476 J. Gratwicke et al.
b
y
 
g
u
e
s
t
 
o
n
 
A
u
g
u
s
t
 
1
4
,
 
2
0
1
5
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 dementia is characterized by superimposition of additional
dysfunction in cholinergic networks (Kehagia et al., 2013).
Management of Parkinson’s disease
dementia
The relative importance of cholinergic network dysfunction
in PDD is reﬂected in current treatment strategies, which
focus on the use of AChEIs, such as rivastigmine, donepezil
and galantamine, to boost cholinergic function. Two large
placebo-controlled trials have shown that rivastigmine sig-
niﬁcantly improves deﬁcits in orienting of attention, vigi-
lance and cognitive ﬂuctuation in patients with PDD (Emre
et al., 2004; Wesnes et al., 2005b), and indeed patients
with more severe attentional deﬁcits appear to respond
best (Wesnes et al., 2005a). These results serve to reinforce
the cholinergic basis of attention deﬁcits in PDD according
to the neural network model. Beneﬁts from AChEIs have
also been demonstrated for executive deﬁcits (action
sequencing, response inhibition and verbal ﬂuency) visuo-
spatial tasks (the Clock Drawing Test) and hallucinations
(Emre et al., 2004; Litvinenko et al., 2008). Whether these
improvements are due to amelioration of the cholinergic
network deﬁcits underlying these cognitive processes, or
are secondary to an overall improvement in attention
assisting other overlapping cognitive functions, or a com-
bination of both, is unknown.
In general, the cognitive beneﬁts seen with the use of
AChEIs in PDD translate into overall improvements in
global cognition and activities of daily living (Ravina
et al., 2005; Rolinski et al., 2012), which are actually
larger than those seen with use of AChEIs in Alzheimer’s
disease (Weintraub et al., 2011). This is most likely due to
the fact that NBM degeneration and resultant cholinergic
network dysfunction is more severe in PDD than
Alzheimer’s disease (Bohnen et al., 2003; Gratwicke
et al., 2013). However, clinical experience indicates that
there is actually substantial variation in the beneﬁcial re-
sponse seen with AChEIs amongst patients with PDD, the
reasons for which are likely multifactorial. Differences in
pharmacokinetics and absorption between individuals,
varying sensitivity to the systemic side effects of AChEIs
(which can be detrimental to their subjective perceived
beneﬁt), and the relative balance of different network dys-
functions amongst individual patients likely all play a part.
With regard to the latter, one would expect greater impact
from AChEIs in patients with PDD with predominant cho-
linergic network dysfunction, but less of an impact in
patients where catecholaminergic network dysfunctions
are similar or equal to cholinergic ones. If so, then it may
be possible to predict which patients will respond better to
AChEIs by characterizing their cognitive symptomatology
according to the neural network model above.
Several other medications also provide limited beneﬁts to
cognitive symptoms in PDD. Levodopa administration im-
proves executive functions requiring cognitive ﬂexibility (as
above), which are mediated by the associative fronto-stri-
atal circuit (which is dopamine depleted early), as well as
the insular. However, it simultaneously worsens executive
functions which involve learning from feedback (prediction
and decision making, reversal and probabilistic classiﬁca-
tion learning) through ‘overdosing’ the relatively more
intact limbic and orbitofrontal circuits in early
Parkinson’s disease (Gotham et al., 1988; Swainson et al.,
2000; Cools et al., 2001; Jahanshahi et al., 2010; see
Dirnberger and Jahanshahi, 2013 for review). Thus clin-
icians titrating levodopa therapy to address motor symp-
toms in PDD also need to be aware of the concurrent
impact this can have on the dysexecutive syndrome.
Furthermore, differences in COMT activity have additional
impact on optimal dopamine replacement strategies, and
whether patients should be genotyped for this purpose
requires further study (Foltynie et al., 2004b).
The mixed NMDA (N-methyl D-aspartate) and nicotinic
acetylcholine receptor antagonist memantine showed
modest beneﬁt on a test of executive control of attention
in PDD in one randomized study (Aarsland et al., 2009),
but signiﬁcant beneﬁts were not conﬁrmed in another larger
trial (Emre et al., 2010). There is also preliminary evidence
from several small clinical trials that the noradrenalin re-
uptake inhibitor atomoxetine may increase arousal levels,
vigilance and deﬁcits in response inhibition in Parkinson’s
disease (Marsh et al., 2009; Weintraub et al., 2010;
Kehagia et al., 2014), in-line with the aforementioned
roles of the noradrenergic network in mediating attention
and cognitive ﬂexibility, respectively. However, the patients
in these trials were not demented, and therefore further
studies in the PDD population are needed to fully ascertain
potential therapeutic beneﬁts.
Finally, there is also growing recognition of the import-
ance of cognitive rehabilitation therapies for managing de-
mentias such as PDD. Several small controlled studies have
shown that sessions of cognitive remediation training or
regular completion of puzzles requiring a high cognitive
load (e.g. Sudoku exercises) leads to broad sustained
improvements in cognitive performance in PD-MCI
patients, particularly on tests of executive functions
(Sinforiani et al., 2004; Sammer et al., 2006; Nombela
et al., 2011; Parı ´s et al., 2011), which is paralleled by
return of frontal cortical activation patterns to normal on
functional MRI (Nombela et al., 2011). Although the im-
provements seen were modest, this result suggests that cog-
nitive training beneﬁts PD-MCI patients, possibly by
reinforcing cognitive strategies, or improving cognitive
reserve, which could be due to plastic effects on the under-
lying neural networks. However, the efﬁcacy of this type of
intervention has not yet been trialled in patients with PDD,
and the potential beneﬁts may be limited in this patient
group who ﬁnd it hard to engage in complex cognitive
exercises on a regular basis. The effects of physical rehabili-
tation and non-invasive brain stimulation on cognitive per-
formance have also been assessed in patients with
Parkinson’s disease with varying, sometimes conﬂicting,
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 results (see Hindle et al., 2013 for review), and so far no
evidence for use of these in PDD exists.
Future directions and
treatment strategies
As this review has shown, the dysfunctional neural net-
works underlying the cognitive symptoms of PDD are
diverse and distributed throughout the brain. There is over-
lap between network functions, each of which depend on
differing primary neurotransmitters. In addition, evidence
suggests that neurotransmitters can modulate the functional
effects of one another (Calabresi et al., 2006), and thereby
damage to one network during the pathogenesis of PDD
may in turn inﬂuence dysfunction in another (Srinivasan
and Schmidt, 2003; Rommelfanger and Weinshenker,
2007). Furthermore, as discussed in detail above, the cellu-
lar-level pathology causing damage to these networks in
PDD is heterogeneous, while the effects of different genes
on the pathophysiology of the disorder is only now being
slowly unravelled.
Given this complex milieu of pathological changes, trans-
mitter interactions and genetic inﬂuences underlying PDD,
it is perhaps not surprising that attempting to treat the
dementia syndrome with drugs targeting single neurotrans-
mitter systems with generalized mechanisms of action have
thus far shown only modest results. We propose that it is
time to refocus the therapeutic drive in PDD to address
cognitive deﬁcits through targeted intervention at the net-
work level. This approach has distinct advantages over the
traditional model of single-ligand-targeted drug therapy.
First, to compensate for deﬁcits in all the neurotransmitter
systems involved in the pathophysiology of PDD using
replacement pharmacotherapy would necessitate polyphar-
macy for patients, with the associated risks of multiple side
effects. Second, the heterogeneity of the underlying molecu-
lar pathology means that pharmacologic agents aiming to
reduce aggregation of abnormal proteins, such as
alpha-synuclein, may be either inappropriate or insufﬁ-
ciently effective in a substantial number of patients.
Novel network-targeted therapies can avoid these difﬁcul-
ties by attempting to modulate the disease process down-
stream at a systems-level to restore normal neural
processing patterns and thereby relieve symptoms.
Such network-modulating therapies are already under
development. One potential route is using deep brain
stimulation. Deep brain stimulation has proven efﬁcacy in
ameliorating the movement symptoms of Parkinson’s dis-
ease by altering processing of motor signals at the neural
network level (Deuschl et al., 2006; Williams et al., 2010;
McConnell et al., 2012). Emerging evidence suggests that it
achieves this by altering brain functional and structural
connectivity via neural plastic mechanisms to return dys-
functional motor network processing back to its natural
state (Fenoy et al., 2014; Kahan et al., 2014; van
Hartevelt et al., 2014). This same approach is now being
employed for modulation of cognitive networks in PDD,
using the NBM as the target structure since the cholinergic
network is involved in all aspects of cognitive impairment
(Freund et al., 2009; Barnikol et al., 2010). The fact that it
is a discrete anatomical structure also makes it easier to
target compared to more diffuse cognitive networks, such
as the fronto-parietal network, where the optimum site of
network modulation is currently unclear. However, caution
should be exercised as the outcome of NBM DBS in
Alzheimer’s disease has been variable, with some patients
experiencing slowing of cognitive decline while others did
not (Kuhn et al., 2015). On the other hand, as mentioned
above, cholinergic deﬁcits in PDD are greater than in
Alzheimer’s disease, which might predict a larger response
in PDD, similar to that seen with AChEI therapy.
Nevertheless, the ability of patients with PDD to give
valid informed consent for surgery must be carefully con-
sidered, and the elevated risks of invasive neurosurgery in
demented patients must be borne in mind (Foltynie and
Hariz, 2010). It should also be remembered that patients
with PDD usually have advanced motor symptoms requir-
ing concurrent therapy, but that they are ineligible for sub-
thalamic nucleus deep brain stimulation for these motor
symptoms due to a risk of worsening verbal ﬂuency and
inhibitory control deﬁcits seen with this target (Witt et al.,
2008). However, the NBM is located directly below the
globus pallidus internus (Gratwicke et al., 2013), a deep
brain stimulation target for alleviation of motor symptoms
without detrimental effects on executive function. This
means that a single pair of electrodes could be placed to
span both structures, allowing therapeutic modulation of
both motor and cognitive networks simultaneously, and
clinical trials of this approach in patients with PDD are
currently ongoing (www.clinicaltrials.gov).
An alternative approach is to try to prevent neurodegen-
eration in speciﬁc cognitive networks in PDD.
Intrahippocampal transplantation of human stem cells
engineered either to differentiate into NBM-like cholinergic
cells (Liu et al., 2013) or produce nerve growth factor (Lee
et al., 2012) has been shown to rescue learning deﬁcits in
rodents, and may hold potential to treat mnemonic deﬁcits
in PDD by countering MTL atrophy. However, results
from rodent studies do not often translate easily to
human research, and the previous mixed results from
instrastriatal transplantation of dopamine-rich foetal stem
cells to treat the dopaminergic deﬁcit in patients with
Parkinson’s disease must be borne in mind (Hagell et al.,
1999). Meanwhile, the development of encapsulated cell
bio-delivery systems and demonstration of their safe
implantation into the NBM of dementia patients provides
a platform for targeted long-term delivery of neurotrophic
factors to prevent degeneration in speciﬁc cognitive net-
works (Wahlberg et al., 2012; Emerich et al., 2014).
However, to enable further development of such thera-
pies for PDD a number of issues still need to be addressed.
The division of cognitive ability into separate domains is in
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 itself largely artiﬁcial and how processes involved in execu-
tive, mnemonic, attention and visual perceptual functions
overlap with one another to produce the conceptualized
‘dementia syndrome’ is far from clear. Studies tend to
have focused on neurochemical correlates of cognitive
decline, but studies examining electrophysiological correl-
ates of cognitive processing both in health and disease are
relatively lacking. Finally, clinical trials of treatments for
PDD to date have evaluated outcomes using a variety of
neuropsychological tests, often validated in non-Parkinson’s
disease populations. Consensus on a standardized testing
battery for PDD research is needed to allow comparisons
between different interventions (Burn et al., 2014).
Moreover, given the ﬂuctuating nature of cognition in
PDD, trials need to incorporate measures of cognition-
related functional abilities to provide a more comprehensive
evaluation of treatment effects.
Conclusion
Although the pathology underlying the motor symptoms of
Parkinson’s disease is now well understood and effective
treatments are available, understanding the dysfunctional
neural processes underlying parkinsonian dementia remains
a formidable challenge, and available treatments are inad-
equate. The frequency and severity of PDD and its impli-
cations for the quality of life of both patient and carer
emphasize the need for greater attention in this area. We
hope that the synthesis of novel insights from across the
spectrum of neuroscience and neurology research that
we present in this manuscript helps shed new light on
this important issue, and provides a framework for new
avenues of research into understanding and potentially
treating PDD at the network level.
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